LOX and hepatocellular carcinoma: We then verified the bioinformatic prediction by an in vitro experimental setting, where overexpression of MIR29A-3p in human HCC cell line HepG2 significantly inhibited the gene and protein expression of LOX (Figure 4A,B), LOXL2 (Figure 4C,D), and VEGFA (Figure 4E,F) (all p < 0.05).